UPC_APP_58035/2024

FLUID DELIVERY DEVICE WITH TRANSCUTANEOUS ACCESS TOOL, INSERTION MECHANISM AND BLOOD GLUCOSE MONITORING FOR USE THEREWITH

Prozessuale & UnteranträgeKostenfestsetzungenMilan LDGenericWritten Phase

Übersicht Entscheidungen Zitate Dokumente Zeitverlauf

Parteien

Kläger

Insulet Corporation

Vertreter: Marc Grunwald

Beklagte

A. Menarini Diagnostics s.r.l.

Vertreter: Martin Kohler

Richter

Pierluigi Perrotti
Alima Zana
Anna-Lena Klein
Uwe Schwengelbeck

Patente

EP4201327
EP 4 201 327

CPC-Codes: A61M5/1723, A61M5/1452, A61M5/158, A61B5/14865, A61M5/14244, F04B9/02, A61B5/14532, A61M2230/201, A61M2005/14506, A61M5/14248, B65D83/761, A61M5/3291…

Sektor: Packaging & Conveying

Ausgang

Abgewiesen

Eingereicht: 24. Okt. 2024

Erste Entscheidung: 30. Dez. 2024

Sprache: English

Milan Local Division dismissed Insulet Corporation's application for a cost decision following the rejection of EOFLOW Co. Ltd.'s intervention request in PI proceedings (EP 4 201 327). The court found the application inadmissible: a cost decision under R. 150 RoP requires a prior decision on costs in principle under R. 118.5 RoP. The order rejecting the intervention (1 October 2024) contained no such costs-in-principle decision, so the cost-determination application lacked the prerequisite under R. 156(e) RoP. Insulet was invited to resubmit once a costs award decision was obtained.

Im UPC-Register öffnen